Dasatinib-Induced Pulmonary Arterial Hypertension

Q4 Medicine

JACC. Case reports Pub Date : 2026-10-21 Epub Date: 2026-08-20 DOI:10.1016/j.jaccas.2026.109931

Nimisha Musthafa Hafeesa MD, Gulbadin Mufti MD, DM, PDF, Harikrishnan Sivadasanpillai MD, DM, DNB

{"title":"Dasatinib-Induced Pulmonary Arterial Hypertension","authors":"Nimisha Musthafa Hafeesa MD, Gulbadin Mufti MD, DM, PDF, Harikrishnan Sivadasanpillai MD, DM, DNB","doi":"10.1016/j.jaccas.2026.109931","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Pulmonary arterial hypertension (PAH) is a serious complication of dasatinib, used for the treatment of chronic myeloid leukemia. Although drug-induced PAH is a recognized entity, the timeline for onset and the degree of recovery on drug withdrawal remain poorly defined.</div></div><div><h3>Case Summary</h3><div>This review includes a series of 5 cases of dasatinib-induced PAH, in which PAH partially or fully reversed on discontinuation of the drug. All cases had documented normal cardiac status at baseline and developed PAH within 12-24 months of initiation. Three cases required pulmonary vasodilators in addition to discontinuation of the drug. The median time to resolution of PAH was 2 (2-4.5) months.</div></div><div><h3>Conclusions</h3><div>Dasatinib-induced PAH is a reversible yet serious condition, which mandates regular screening of patients for early recognition of the condition. Larger series with longer follow-up are mandated for better understanding of the factors associated with the risks and severity of the condition.</div></div>","PeriodicalId":14792,"journal":{"name":"JACC. Case reports","volume":"31 42","pages":"Article 109931"},"PeriodicalIF":0.0000,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666084926030925","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Pulmonary arterial hypertension (PAH) is a serious complication of dasatinib, used for the treatment of chronic myeloid leukemia. Although drug-induced PAH is a recognized entity, the timeline for onset and the degree of recovery on drug withdrawal remain poorly defined.

Case Summary

This review includes a series of 5 cases of dasatinib-induced PAH, in which PAH partially or fully reversed on discontinuation of the drug. All cases had documented normal cardiac status at baseline and developed PAH within 12-24 months of initiation. Three cases required pulmonary vasodilators in addition to discontinuation of the drug. The median time to resolution of PAH was 2 (2-4.5) months.

Conclusions

Dasatinib-induced PAH is a reversible yet serious condition, which mandates regular screening of patients for early recognition of the condition. Larger series with longer follow-up are mandated for better understanding of the factors associated with the risks and severity of the condition.

查看原文本刊更多论文

达沙替尼诱发肺动脉高压。

肺动脉高压（PAH）是用于治疗慢性髓性白血病的达沙替尼的严重并发症。虽然药物引起的多环芳烃是公认的实体，但发病时间和停药后恢复的程度仍然不明确。病例总结：本综述包括一系列5例达沙替尼诱导的PAH，其中PAH在停药后部分或完全逆转。所有病例在基线时心脏状态正常，并在开始治疗的12-24个月内发展为PAH。3例患者除停药外，还需使用肺血管扩张剂。PAH消退的中位时间为2（2-4.5）个月。结论：达沙替尼诱导的PAH是一种可逆但严重的疾病，需要定期筛查患者以早期识别这种疾病。为了更好地了解与风险和病情严重程度相关的因素，需要进行更大规模、更长的随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊